Pipeline
At Fibrocor Therapeutics, we are not just treating fibrosis; we put patients first in our drug discovery and clinical development process. Our unwavering commitment to research and innovation has led us to discover the most promising and effective drug candidates in fibrosis treatment, setting us apart as industry leaders.
Understanding Kidney Health
Healthy kidneys are remarkable organs that filter waste, regulate blood pressure, and maintain fluid balance in the body. Each kidney contains about one million nephrons working tirelessly to keep us healthy.
Understanding Kidney Disease
Chronic kidney disease affects millions worldwide, causing progressive damage to these vital organs. Visible changes include scarring, cysts, and tissue deterioration that compromise kidney function.
Lead FIB992
Kidney Allograft Fibrosis
First-in-class, highly selective, small molecule kinase inhibitor of a novel target. The target has been validated by multiple academic teams in fibrotic kidney disease models. The target is expressed at low levels in healthy tissues and strongly upregulated in fibrotic conditions. It is a key gate keeper on the matrix stiffness pathway and inhibiting this pathway decreases the secretion of many profibrotic cytokines like TGFβ and CTGF.
FIB991 is a modulator of the YAP/TAZ, the primary mechanotransduction pathway in fibrotic tissues. Inhibition of FIB991 blocks the YAP/TAZ pathway, shutting down the activation of fibroblasts and stopping the progression of fibrosis.
FIB991
Chronic Kidney Disease
FIB918
Alport Syndrome
FIB918 is a key protein that promotes fibrosis by playing a critical role in the differentiation and function of myofibroblasts, the cells responsible for scar tissue formation. It is overexpressed in fibrotic diseases in kidneys, liver and lung, where it enhances myofibroblast characteristics like adhesion, contractility, and collagen production.